Mediphron Discovers Leading Substance for Dementia Treatment... "Green Light for Drug Development"

[Asia Economy Reporter Hyunseok Yoo] Mediphron Divity, a company specializing in innovative drug development, announced on the 8th that it has succeeded in discovering lead compounds for the development of dementia treatment drugs.

Mediphron, through a three-year joint research project with Chonnam National University, succeeded in discovering lead compounds with a mechanism that inhibits tau phosphorylation, thereby preventing tau protein denaturation and aggregation. After an optimization process including its own preclinical experiments, the company plans to establish candidate substances within this year.

In particular, tau mechanism-based therapeutics have the potential to be applied as treatments regulating glucose metabolism, which is also cited as another cause of Alzheimer's disease dementia. Candidate compounds targeting tau protein are currently being developed by global pharmaceutical companies such as Eisai and Janssen, with mechanisms that prevent hyperphosphorylation of tau protein.

Youngdong Yoo, head of Mediphron Research Institute, said, "While it remains true that beta-amyloid protein is a cause of dementia, recent research shows that tau protein induces Alzheimer's dementia much more strongly. Following the pipeline mechanism that inhibits beta-amyloid aggregation and reduces toxicity, which has already been applied in clinical trials, we have now succeeded in securing candidate compounds targeting tau protein, thereby expanding our pipeline to more than two that can respond to the scientific basis of Alzheimer's dementia treatment research." He added, "We will definitely succeed in developing dementia treatment drugs currently under development and leap forward as a global dementia treatment drug development company."

This content was produced with the assistance of AI translation services.